These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 16448452)

  • 1. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease.
    Palekar NA; Naus R; Larson SP; Ward J; Harrison SA
    Liver Int; 2006 Mar; 26(2):151-6. PubMed ID: 16448452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease.
    Miele L; Forgione A; La Torre G; Vero V; Cefalo C; Racco S; Vellone VG; Vecchio FM; Gasbarrini G; Rapaccini GL; Neuman MG; Grieco A
    Transl Res; 2009 Oct; 154(4):194-201. PubMed ID: 19766963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease.
    Sorbi D; Boynton J; Lindor KD
    Am J Gastroenterol; 1999 Apr; 94(4):1018-22. PubMed ID: 10201476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical and histological features of non-alcoholic fatty liver disease].
    Shi JP; Xun YH; Hu CB; Zhang L; Liu H; Lou GQ; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):812-6. PubMed ID: 19958638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.
    Wieckowska A; Zein NN; Yerian LM; Lopez AR; McCullough AJ; Feldstein AE
    Hepatology; 2006 Jul; 44(1):27-33. PubMed ID: 16799979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis.
    Shimada M; Kawahara H; Ozaki K; Fukura M; Yano H; Tsuchishima M; Tsutsumi M; Takase S
    Am J Gastroenterol; 2007 Sep; 102(9):1931-8. PubMed ID: 17511754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
    Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
    Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors for nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
    Fierbinteanu-Braticevici C; Baicus C; Tribus L; Papacocea R
    J Gastrointestin Liver Dis; 2011 Jun; 20(2):153-9. PubMed ID: 21725512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
    McPherson S; Stewart SF; Henderson E; Burt AD; Day CP
    Gut; 2010 Sep; 59(9):1265-9. PubMed ID: 20801772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease.
    Lemoine M; Ratziu V; Kim M; Maachi M; Wendum D; Paye F; Bastard JP; Poupon R; Housset C; Capeau J; Serfaty L
    Liver Int; 2009 Oct; 29(9):1431-8. PubMed ID: 19422483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High adiponectin and TNF-alpha levels in moderate drinkers suffering from liver steatosis: comparison with non drinkers suffering from similar hepatopathy.
    Stejskal D; Růzicka V; Fanfrdlová G; Kolár V; Bartek J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Jun; 149(1):93-9. PubMed ID: 16170395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.
    Angulo P; Keach JC; Batts KP; Lindor KD
    Hepatology; 1999 Dec; 30(6):1356-62. PubMed ID: 10573511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease.
    Kaneda H; Hashimoto E; Yatsuji S; Tokushige K; Shiratori K
    J Gastroenterol Hepatol; 2006 Sep; 21(9):1459-65. PubMed ID: 16911693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of serum hepatic fibrosis markers in the diagnosis of nonalcoholic steatohepatitis (NASH).
    Sasaki N; Ueno T; Morita Y; Nagata E; Sata M
    Hepatogastroenterology; 2006; 53(71):678-81. PubMed ID: 17086867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leptin levels in nonalcoholic steatohepatitis and chronic hepatitis C.
    Giannini E; Botta F; Cataldi A; Tenconi GL; Ceppa P; Barreca T; Testa R
    Hepatogastroenterology; 1999; 46(28):2422-5. PubMed ID: 10522010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis.
    Bahcecioglu IH; Yalniz M; Ataseven H; Ilhan N; Ozercan IH; Seckin D; Sahin K
    Hepatogastroenterology; 2005; 52(65):1549-53. PubMed ID: 16201116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease in severely obese subjects.
    Gholam PM; Flancbaum L; Machan JT; Charney DA; Kotler DP
    Am J Gastroenterol; 2007 Feb; 102(2):399-408. PubMed ID: 17311652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive clinical model for the diagnosis of nonalcoholic steatohepatitis in overweight and morbidly obese patients undergoing bariatric surgery.
    Pirvulescu I; Gheorghe L; Csiki I; Becheanu G; Dumbravă M; Fica S; Martin S; Sarbu A; Gheorghe C; Diculescu M; Copăescu C
    Chirurgia (Bucur); 2012; 107(6):772-9. PubMed ID: 23294957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease.
    Hossain N; Afendy A; Stepanova M; Nader F; Srishord M; Rafiq N; Goodman Z; Younossi Z
    Clin Gastroenterol Hepatol; 2009 Nov; 7(11):1224-9, 1229.e1-2. PubMed ID: 19559819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease.
    Yalamanchili K; Saadeh S; Klintmalm GB; Jennings LW; Davis GL
    Liver Transpl; 2010 Apr; 16(4):431-9. PubMed ID: 20373454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.